
浏览全部资源
扫码关注微信
1.安徽中医药大学 中医学院,合肥 230038
2.安徽中医药大学 教育部新安医学重点实验室,合肥 230038
喻锦,在读硕士,从事经方治疗疑难病症机制研究,E-mail:916815407@qq.com
储全根,博士,教授,从事经方治疗疑难病症机制研究,E-mail:286428483@qq.com
收稿日期:2021-12-15,
网络出版日期:2022-02-11,
纸质出版日期:2022-05-05
移动端阅览
喻锦,储全根,李飞翔等.抵当陷胸汤对高糖诱导心肌微血管内皮细胞损伤的影响[J].中国实验方剂学杂志,2022,28(09):52-58.
YU Jin,CHU Quan-gen,LI Fei-xiang,et al.Effect of Didang Xianxiong Decoction on Cardiac Myocardial Microvascular Endothelial Cell Injury Induced by High Glucose[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(09):52-58.
喻锦,储全根,李飞翔等.抵当陷胸汤对高糖诱导心肌微血管内皮细胞损伤的影响[J].中国实验方剂学杂志,2022,28(09):52-58. DOI: 10.13422/j.cnki.syfjx.20220805.
YU Jin,CHU Quan-gen,LI Fei-xiang,et al.Effect of Didang Xianxiong Decoction on Cardiac Myocardial Microvascular Endothelial Cell Injury Induced by High Glucose[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(09):52-58. DOI: 10.13422/j.cnki.syfjx.20220805.
目的
2
基于高糖诱导的心肌微血管内皮细胞(CMECs)模型,观察抵当陷胸汤对其损伤的影响,并探讨其相关作用机制。
方法
2
采用体外培养大鼠原代心肌细胞,给予33 mmol·L
-1
葡萄糖造模,造模成功后随机分为模型组(葡萄糖终浓度为33 mmol·L
-1
)、正常组、抵当陷胸汤低剂量组(葡萄糖+5%抵当陷胸汤含药血清)、抵当陷胸汤中剂量组(葡萄糖+10%抵当陷胸汤含药血清)、抵当陷胸汤高剂量组(葡萄糖+20%抵当陷胸汤含药血清)和阿拉氯胺(ALT-711)组(葡萄糖+10%ALT-711含药血清)。采用噻唑蓝(MTT)比色法检测含药血清对CMECs增殖的影响;实时荧光定量聚合酶链式反应(Real-time PCR)检测各组c-Jun mRNA相对表达水平;蛋白免疫印迹法(Western blot)检测磷酸化蛋白质酪氨酸激酶1(p-JAK1)、磷酸化信号转导和转录激活因子1(p-STAT1)、转化生长因子-
β
1
(TGF-
β
1
)蛋白的表达水平。
结果
2
与正常组比较,模型组细胞中c-Jun mRNA、p-JAK1、p-STAT1及TGF-
β
1
蛋白的表达均显著升高(
P
<
0.01);与模型组比较,各治疗组细胞中c-Jun mRNA表达水平显著降低(
P
<
0.01),抵当陷胸汤中、高剂量组及ALT-711组中p-JAK1、p-STAT1蛋白表达水平均明显降低(
P
<
0.05,
P
<
0.01),抵当陷胸汤低剂量组变化差异无统计学意义,各用药组TGF-
β
1
蛋白均明显降低(
P
<
0.05,
P
<
0.01),且抵当陷胸汤中、高剂量组较低剂量组下降明显。
结论
2
抵当陷胸汤对高糖损伤的CMECs起到保护作用,其机制可能与降低细胞内JAK/STAT信号转导通路活性有关。
Objective
2
This study was designed to observe the effect of Didang Xianxiong decoction on the cardiac myocardial microvascular endothelial cells (CMECs) injury, and to explore its related mechanism based on the CMECs model induced by high glucose.
Method
2
Rat primary myocardial cells were cultured
in vitro
and 33 mmol·L
-1
glucose was added for modeling. After modeling, the rats were randomly divided into model group (final glucose concentration: 33 mmol·L
-1
), normal group, Didang Xianxiong decoction low dose group (glucose + 5% Didang Xianxiong decoction containing serum), Didang Xianxiong decoction medium dose group (glucose+10% Didang Xianxiong decoction containing serum), Didang Xianxiong decoction high dose group (glucose+20% Didang Xianxiong decoction containing serum) and alagebrium chloride (ALT-711) group (glucose+10% ALT-711 containing serum). The influence of drug-containing serum on the proliferation of CMECs was detected by MTT tetrazolium salt colorimetric assay. The relative mRNA expression of c-Jun was detected by real-time fluorescence quantitative polymerase chain reaction (Real-time PCR). The protein expression of phosphorylated Janus kinase 1 (p-JAK1), phosphorylated signal transducer and activator of transcription 1 (p-STAT1) and transforming growth factor-
β
1
(TGF-
β
1
) was determined by Western blot.
Result
2
Compared with the conditions in normal group, the mRNA expression of c-Jun and protein expression of p-JAK1, p-STAT1 and TGF-
β
1
were up-regulated in model group (
P
<
0.01). Compared with model group, all treatment groups had decreased mRNA expression of c-Jun (
P
<
0.01). Didang Xianxiong decoction medium and high dose groups and ALT-711 group showed reduced protein expression of p-JAK1 and p-STAT1 (
P
<
0.05,
P
<
0.01), while there was no significant change in Didang Xianxiong decoction low dose group. TGF-
β
1
protein expression was lowered in all treatment groups (
P
<
0.05,
P
<
0.01), and the decrease was more significant in Didang Xianxiong decoction medium and high dose groups than Didang Xianxiong decoction low dose group.
Conclusion
2
Didang Xianxiong decoction can protect CMECs with high glucose-induced injury, and the mechanism may be related to reducing the activity of JAK/STAT signaling pathway in cells.
JIA G H , WHALEY-CONNELL A , SOWERS J R . Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistanceinduced heart disease [J]. Diabetologia , 2018 , 61 ( 1 ): 21 - 28 .
苏中州 , 吴铿 . 晚期糖基化终末产物在糖尿病心肌病发病机制中的作用研究进展 [J]. 医学综述 , 2013 , 19 ( 14 ): 2597 - 2599 .
李晓燕 , 钱玲玲 , 王如兴 . 晚期糖基化终末产物对糖尿病心肌病影响的研究进展 [J]. 中国分子心脏病学杂志 , 2021 , 21 ( 2 ): 3895 - 3898 .
BOENGLER K , BUECHERT A , HEINEN Y , et al . Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice [J]. Circ Res , 2008 , 102 ( 1 ): 131 - 135 .
轩云 . “痰瘀同治”干预糖尿病大鼠心肌AGEs-RAGE轴所致病变的作用机理研究 [D]. 合肥 : 安徽中医药大学 , 2020 .
杨爽 . 基于JAK/STAT通路探讨桂枝芍药知母汤对TNF- α 诱导的MH7A细胞的抗炎作用 [D]. 成都 : 成都中医药大学 , 2019 .
蔡正银 , 储全根 , 储俊 , 等 . 化痰化瘀通络法对糖尿病大鼠心肌微血管和细胞外间质的影响及机制研究 [J]. 中国中西医结合杂志 , 2020 , 40 ( 8 ): 948 - 954 .
蔡正银 , 储全根 , 轩云 , 等 . 抵当陷胸汤对糖尿病大鼠肝脏TGF- β 1 /Smad3信号通路的影响 [J]. 安徽中医药大学学报 , 2020 , 39 ( 3 ): 56 - 59 .
李飞翔 , 储全根 , 王盼 , 等 . 痰瘀同治调控TLR4/NF- κ B/I κ B通路对糖尿病大鼠心肌炎症反应的影响 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 22 ): 59 - 64 .
CHEN N X , SRINIVASAN S , O'NEILL L , et al . Effect of advanced glycation end-products (AGE) lowering drug ALT-711 on biochemical, vascular, and bone parameters in a rat model of CKD-MBD [J]. J Bone Miner Res , 2020 , 35 ( 3 ): 608 - 617 .
徐叔云 . 药理实验方法学 [M]. 北京 : 人民卫生出版社 , 2002 : 192 .
辛毅 , 刘小希 , 赵伟 , 等 . 差速贴壁法分离兔骨髓源性间充质干细胞和内皮祖细胞及其生物学特性的研究 [J]. 中国实验血液学杂志 , 2013 , 21 ( 3 ): 746 - 753 .
许笑雯 , 储全根 , 储俊 , 等 . 痰瘀同治法对糖尿病大鼠心肌微血管病变AGEs/RAGE轴及氧化应激的影响 [J]. 南方医科大学学报 , 2021 , 41 ( 10 ): 1527 - 1533 .
张驰 . 冠心病合并2型糖尿病中医证型分布特点及与冠脉病变的相关性研究 [D]. 北京 : 北京中医药大学 , 2019 .
常成成 , 李红蓉 , 刘红利 , 等 . 脉络学说营卫交会生化理论探讨 [J]. 中医杂志 , 2017 , 58 ( 1 ): 2 - 5 .
李禄伟 , 于健 . 糖基化终末产物与糖尿病微血管病变的研究进展 [J]. 华夏医学 , 2020 , 33 ( 3 ): 173 - 177 .
程婕 . “痰瘀同治”对糖尿病大鼠心肌AGEs蓄积及所致病变的干预作用研究 [D]. 合肥 : 安徽中医药大学 , 2019 .
朱立 , 赵进喜 , 刘宁 , 等 . 水蛭虻虫,活血可通络;[庶虫]虫鳖甲,化瘀能散结 [J]. 环球中医药 , 2019 , 12 ( 9 ): 1339 - 1341 .
国家药典委员会 . 临床用药须知·中药饮片卷 [M]. 北京 : 中国医药科技出版社 , 2011 : 833 .
李欣 , 张杰群 , 房辉 . 链脲佐菌素致糠尿病大鼠心肌结缔组织生长因子及蛋白激酶C表达的实验研究 [J]. 海南医学院学报 , 2013 , 19 ( 8 ): 1012 - 1015 .
KIU H , NICHOLSON S E . Biology and significance of the JAK/STAT signalling pathways [J]. Growth Factors , 2012 , 30 ( 2 ): 88 - 106 .
MONTERO P , MILARA J , ROGER I , et al . Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms [J]. Int J Mol Sci , 2021 , 22 ( 12 ): 6211 .
HUANG J S , GUH J Y , HUNG W C , et al . Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells [J]. Biochem J , 1999 , 342 (Pt 1 ): 231 - 238 .
HILFIKER-KLEINER D , HILFIKER A , DREXLER H . Many good reasons to have STAT3 in the heart [J]. Pharmacol Ther , 2005 , 107 ( 1 ): 131 - 137 .
SNYDER M , HUANG X Y , ZHANG J J . Identification of novel direct Stat3 target genes for control of growth and differentiation [J]. J Biol Chem , 2008 , 283 ( 7 ): 3791 - 3798 .
晁鹏 . JAK/STAT信号转导通路与心力衰竭的研究进展 [J]. 心血管病学进展 , 2017 , 38 ( 6 ): 729 - 735 .
WANG Y J , LI Y , WANG X L , et al . Effect of total flavonoids of oxytropis falcata bunge on the expression of p-JAK1-and p-STAT1-related proteins in idiopathic pulmonary fibrosis [J]. Evid Based Complement Alternat Med , 2020 , 2020 : 2407239 .
芦文娟 , 方敬爱 , 孙艳艳 , 等 . 益肾胶囊对糖尿病肾病大鼠肾组织JAK/STAT信号通路的影响 [J]. 中国中西医结合肾病杂志 , 2011 , 12 ( 7 ): 574 - 577 .
WANG L , LI J , LI D . Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway [J]. Int J Clin Exp Pathol , 2015 , 8 ( 1 ): 466 - 473 .
陈冰 , 彭娇娇 , 蔡启航 , 等 . 不同胶原蛋白及TGF- β 1 参与糖尿病心肌纤维化的形成 [J]. 徐州医学院学报 , 2015 , 35 ( 5 ): 281 - 285 .
范美玲 , 应苗法 , 赵蕊 , 等 . TGF- β 信号通路在纤维化疾病中的作用研究进展 [J]. 解放军医学杂志 , 2020 , 45 ( 11 ): 1171 - 1177 .
0
浏览量
22
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621